{"id":"NCT00811473","sponsor":"AstraZeneca","briefTitle":"Pediatric Bipolar Depression","officialTitle":"An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2008-12-19","resultsPosted":"2011-12-01","lastUpdate":"2014-07-15"},"enrollment":193,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Depression"],"interventions":[{"type":"DRUG","name":"Quetiapine XR","otherNames":["Seroquel XR"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Quetiapine XR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUELÂ® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with bipolar depression and if so, how it compares with placebo (a non-active tablet, like a sugar pill, that looks like quetiapine).","primaryOutcome":{"measure":"Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57)","timeFrame":"Will be scored at all visits. the analysis is the change from baseline to the final assessment at day 57","effectByArm":[{"arm":"Quetiapine XR","deltaMin":-29.6,"sd":1.65},{"arm":"Placebo","deltaMin":-27.3,"sd":1.6}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":48,"countries":["United States","Colombia","India","Mexico","Serbia","South Africa","Taiwan"]},"refs":{"pmids":["24956042"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=276&filename=CSR-D144AC00001.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=276&filename=D144AC00001_Redacted_RRB_1516423827582625983.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Headache","Sedation","Somnolence","Dizziness","Nasoparyngitis"]}}